enGenes Biotech has developed -eXchange™ as an optimized solution for the cost-effective production of recombinant proteins and plasmid DNA that are free of antibiotic resistance genes.
It can be used in conjunction with other enGenes technology platforms, such as -eXpress™ and enGenes-eXtra™ for enhanced production of very high-quality plasmid DNA (pDNA) and recombinant proteins, allowing for faster-track production of enzymes and antigen development, for instance.
enGenes-eXpress™
Leveraged from enGenes’ world-class experience in cutting-edge genetic engineering, combined with a broad expertise in bioprocess engineering, the enGenes-eXpress™ Escherichia coli (E.coli) proprietary technology forms a production platform that delivers up to five times higher soluble product yields and easier downstream processing.
enGenes-eXpress™ is a patented next-generation, growth-decoupled Escherichia coli expression platform that enables scalable, cost-effective production of difficult-to-express or toxic recombinant proteins and plasmid DNA, reducing cost of goods sold (COGS) by up to 80%.
The technology is based on a genetically modified host cell variant of BL21 (DE3) that allows introduction of standard expression vectors (with T7 promoter) without cumbersome media adaptations. Using this procedure makes it possible to generate significantly higher specific and volumetric yields compared to the previous ‘gold standard’ E. coli BL21 (DE3).
For more information read here: https://www.pharmaceutical-networking.com/engenes-exchange-technology-for-antibiotic-resistance-free-recombinant-proteins-and-plasmid-dna/
Commentaires